Ms. Dikla Czaczkes Akselbrad serves as the Chief Executive Officer of PolyPid after serving as the company’s EVP and CFO since 2017, leading the company’s initial public offering on the Nasdaq Global Market in June 2020. Dikla brings more than 20 years of experience leading life sciences companies through critical international strategic, financial and business transitions, including raising over $350 million in various forms in her prior executive roles. Before joining PolyPid in 2014, Dikla served as CFO of Compugen Ltd. (NASDAQ & TASE: CGEN) after serving as CFO of Packet Technologies Ltd., and an audit manager at Ernst & Young Israel. She received a B.A. in accounting and economics and an MBA from Tel-Aviv University, and is a certified public accountant in Israel.
Dr. Emanuel has vast experience in biotechnology projects, including development of drug delivery systems and immunology. His extensive expertise includes immunotherapy, vaccines, immunodiagnostics, systemic and local drug-delivery, and medical devices. Dr. Emanuel has a number of approved patents in the field of drug delivery and diagnostics. Dr. Emanuel is a co-founder of PolyPid and served as its CEO during the company’s first three years. He received his Ph.D. degree from the Faculty of Medicine at the Hebrew University of Jerusalem.
Ms. Hazan has over 20 years of diversified managerial experience in the Regulatory Affairs field. Ms. Hazan has vast experience in registration submissions of different pharmaceutical dosage forms and in different markets such as US, EU, CA, IL and rest of the world. Previously she held Regulatory Affairs managerial positions at Teva Pharmaceuticals Ltd. (Head of RA Department) as well as harmonization of RA procedures globally (as part of Global RA compliance), and Dexcel Pharma Ltd. (RA Manager). Ms. Hazan holds an M.Sc. degree in Physiology and Pharmacology from Sackler Faculty of Medicine, Tel Aviv University.
Ori has over 15 years of international experience in the pharmaceuticals industry with experience ranging from corporate strategy and business development to marketing and market access. Prior to joining Polypid Ori spent 10 years at Teva Pharmaceuticals with his last role being Senior Director of Oncology Marketing where he led the launch of several oncology products. Earlier in his career Ori served as the Head of Market Access for Teva in Canada and as Chief of Staff to the CEO of Teva’s global generics business. Ori started his career as a biotech engineer both in Israel and the US.
Ori holds a B.Sc. degree in Biotechnology Engineering from the Ben-Gurion University and an MBA from Duke University’s Fuqua School of Business.
Dr. Hagai is a seasoned Life Sciences executive with 20 years of successful track record in corporate Marketing & Business Development positions at various big pharma companies. Before joining Polypid, he served two years as VP Business development for Biotech Company at Aurum Ventures, the technology investment arm of Morris Kahn. Previously he held senior global positions at Teva Pharmaceuticals including Director of Global Strategic Marketing for innovative drugs in Multiple Sclerosis and Global head of Women’s Health Portfolio for EMIA-APAC region. Dr. Hagai holds a Pharm.D, is a Doctor in Clinical Biology and also holds a Master in Marketing (Paris V University).
Mr. Valdman has more than 30 years of experience in pharmaceutical industry in various companies, including Teva and others. His focus were positions related to research, development and manufacturing. His last role prior to joining PolyPid was the Chief Operating Officer.
Mr. Valdman holds a B.A. and M.A. in Science, both from Volgograd State Technical University.